A study by Loktionov et al. [35] found an insignificant reduction in developing CRC compared with individuals with the 5G5G genotype among 206 patients with CRC and 355 controls for PAI-1 4G5G heterozygotes (OR = 0.82; 95% CI: 0.49–1.35) and no risk reduction for 4G4G carriers (OR = 1.05; 95% CI: 0.60–1.82) compared with individuals with the 5G5G genotype. The gene discussed is SERPINE1; the disease is colorectal carcinoma.